Remdesivir should always be administered via IV (intravenous) infusion only. The medication shouldn’t be administered as an IM (intramuscular) injection.
REMDESIVIR is basically an adenosine nucleoside triphosphate analog. Which was originally developed for treating hepatitis C and was then tested against Ebola virus disease and also Marburg virus disease, but was ineffective for all of these viral infections.
On 1 May 2020, the U.S. FDA (Food and Drug Administration) granted Gilead Emergency Use Authorization for remdesivir to be distributed and used by licensed health care providers to treat adults and children hospitalized with severe COVID‐19.
On 4th June 2020, this drug (GS-5734) was approved to be distributed and used for the treatment of COVID-19 cases. It has an inhibitory effect on human coronavirus and on pathogenic animals. This medication is also effective against severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus.
Remdesivir should always be administered via IV (intravenous) infusion only. The medication shouldn’t be administered as an IM (intramuscular) injection.
COVID‑19: In several studies, some of the most common side effects of remdesivir reported which are as: respiratory failure and organ impairment, including low potassium, low albumin, low count of red blood cells, low count of platelets, and yellow discoloration of the skin. Other observed adverse effects are elevated transaminase levels in the blood (liver enzymes), gastrointestinal distress, and infusion site reactions.
A few more possible adverse reactions of remdesivir include: vomiting, low blood pressure, nausea, sweating, shivering and Increases in levels of liver enzymes.
Care should be exercised in the handling of REMDESIVIR. It should not be opened or crushed. Diluted solution should be stored for infusion up to 4 hours at room temperature (20°C to 25°C [68°F to 77°F]) or 24 hours at refrigerated temperature (2°C to 8°C [36°F to 46°F]).
Remdesivir is partially metabolized by the cytochrome P450 enzymes CYP2C8, CYP3A4 and CYP2D6. Blood plasma concentrations of the remdesivir are expected to decrease if it is administered together with cytochrome P450 inducers such as rifampicin, carbamazepine, phenobarbital, phenytoin, primidone, and St John’s wort.
Remdesivir is mainly a nucleoside ribonucleic acid (RNA) polymerase inhibitor.
The active ingredient is Remdesivir, and the inactive ingredients are betadex sulfobutyl ether sodium, water for Injection.
Before taking Remdesivir medicine, one should tell the doctor the following medical conditions:
Have kidney problems
Have liver problems
Pregnant or plan to become pregnant
Allergic to ingredients of Remdesivir
Nausea vomiting and increased liver enzymes are a common side effect.
Do not open or crush the Injection.
The diluted solution should be stored for infusion up to 4 hours at room temperature 20°C to 25°C [68°F to 77°F] or 24 hours at refrigerated temperature 2°C to 8°C [36°F to 46°F].
All Trademark and Brand that appear on the website belong to their respective owners and Ikris Pharma Network does not lay and claim on them we only provide Information. Remdesivir is a pharmaceutical drug that legally requires a medical prescription to be dispensed.
Following Information meant for Wholesalers, Suppliers, Exporters, Doctors, Comparator Supplies, Hospitals, Generic, Brand, Corporate Sourcing, reseller and Pharmacies.